Join Now

Utah Life Sciences News & Events

IONIQ Science 2022 year-end update

December 20, 2022

For IONIQ Sciences, 2022 was another big year.

As we respond to the FDA’s substantive review of our De Novo application for the ‘breakthrough‘ IONIQ ProLung Test, powerful macroeconomic factors are highlighting the importance of early cancer detection. Despite uncertain conditions in the financial market, we have a compelling message for potential institutional and strategic investors at the right time.

Science and Clinical Evidence

  • Thanks to your help and our trial sites, we’ve grown our clinical evidence library for lung, breast and GI cancer plus healthy volunteers by 40% in 2022. 
  • We’re still scanning healthy volunteers and those with cancer especially from different racial and ethnic identities to represent our broadly diverse USA population. Get the details on Facebook, Linkedin or email us for details. 
  • In early-2022, Dr. Rex Yung (IONIQ Chief Medical Officer), Natasha Andreasen (IONIQ Clinical Coordinator) and Dr. Amit Goyal (physician investigator from Loyola Univ Med Ctr) presented our latest lung cancer clinical trial results at the American Thoracic Society (ATS) medical meeting. 


  • In Feb 2022, the IONIQ team – alongside a supporting cast of experts, consultants and partners – submitted the De Novo application for our ‘breakthrough‘ lung cancer system to the FDA. 
  • Our team and consultants are currently working through the FDA’s substantive review of our De Novo application. We will share an update at the conclusion of the FDA review process. 

Product Pipeline – first lung, then breast and ultimately Multi-Cancer

Market attractiveness

  • In early 2022, we successfully addressed the terms of our outstanding convertible notes and the vast majority of our warrants were either exercised or expired. All of this increases our market attractiveness to potential institutional and strategic partners. 
  • In early 2022, we partnered with Edison Group as our Investor Relations Advisor. This relationship has already proven beneficial. 
  • During 2022, we were recognized and awarded seven times for our achievements in modernizing early stage cancer detection. It’s inspiring! 

Macroeconomic factors

Links to all of our corporate social media accounts, including our new Instagram account, can be found at the bottom of this email (@IONIQsciences).